GHRP-6 Mechanism of Action
How GHRP-6's original, less-selective ghrelin-receptor binding produces a broader hormonal and appetite research profile than newer secretagogues.
An Early, Broadly-Acting Ghrelin Receptor Agonist
GHRP-6 is a synthetic hexapeptide developed by Cyril Bowers and colleagues at Tulane University in the 1980s, as part of the original research program that established synthetic ghrelin-receptor agonists as a distinct class of growth hormone secretagogues. It binds GHSR1a, the ghrelin receptor, the same receptor later studied for Ipamorelin and hexarelin, but predates both by well over a decade.
A Considerably Less Selective Binding Profile
Where later compounds like Ipamorelin were specifically engineered for receptor selectivity, GHRP-6's binding conformation activates a broader range of GHSR1a's downstream signaling. Alongside reliable growth hormone release, this produces well-documented and reproducible spikes in cortisol, ACTH, and prolactin — the exact off-target hormonal-axis activation that later secretagogue research specifically aimed to eliminate.
A Pronounced Appetite-Stimulating (Orexigenic) Effect
GHRP-6 also produces a significant and reliably reproducible increase in appetite, mediated through ghrelin-receptor activation in the hypothalamus. This orexigenic effect is substantially more pronounced with GHRP-6 than with more selective ghrelin-receptor agonists, and is itself a distinct area of research interest separate from GHRP-6's growth-hormone-releasing activity.
How This Differs From Ipamorelin
GHRP-6 and Ipamorelin act on the identical receptor, but Ipamorelin was specifically engineered to eliminate the off-target cortisol, ACTH, and prolactin activation that characterizes GHRP-6 — making the comparison between the two a useful illustration of how binding-conformation differences at the same receptor can produce very different research profiles. GHRP-6's pharmacology also helped guide the eventual cloning of the growth hormone secretagogue receptor itself.
- Ghrelin-receptor (GHSR1a) pharmacology research
- Growth hormone secretagogue mechanism studies
- Orexigenic (appetite-stimulating) effect research
- Comparative receptor-selectivity research vs Ipamorelin
GHRP-6 mechanism questions
Why does GHRP-6 cause cortisol and prolactin spikes?
GHRP-6's binding conformation at the ghrelin receptor (GHSR1a) activates a broader range of downstream signaling than more selective agonists, producing well-documented off-target increases in cortisol, ACTH, and prolactin alongside growth hormone release.
How does GHRP-6 differ from Ipamorelin if they act on the same receptor?
Both bind GHSR1a, but Ipamorelin was specifically engineered for a more selective binding conformation that activates growth-hormone release without significantly triggering GHRP-6's off-target cortisol, ACTH, and prolactin effects.
Interested in GHRP-6?
See pricing and order on the product page, or browse our other GHRH and growth-hormone peptides.